Stoke Therapeutics (STOK) Preferred Shares (2018)

Stoke Therapeutics' (STOK) quarterly Preferred Shares came in at $28.9 million in Q4 2018.

Stoke Therapeutics (STOK) Preferred Shares (2018) Analysis & Trends

Stoke Therapeutics' Preferred Shares history runs 1 years deep, the most recent figure standing at $28.9 million for Q4 2018.

On a quarterly basis, Preferred Shares changed N/A year-over-year to $28.9 million in Q4 2018; TTM through Dec 2018 was $28.9 million, a N/A change from a year earlier, with the FY2018 full-year figure at $28.9 million, changed N/A from the prior year.
Preferred Shares steadied at $28.9 million in Q4 2018 per STOK's latest filing.
Across five years, Preferred Shares topped out at $28.9 million in Q4 2018 and bottomed at $28.9 million in Q4 2018.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Stoke Therapeutics	1.87 Bn	1.53 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2018	28.88 Mn